Trial Profile
Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2010
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil/hydrochlorothiazide (Primary)
- Indications Diabetic nephropathies; Hypertension; Proteinuria
- Focus Therapeutic Use
- Acronyms CHILI-T2D
- 01 May 2010 Results will be published in Clinical Drug Investigations.
- 15 Apr 2010 New trial record.